Structure Therapeutics Inc (GPCR)

$21.56 +1.36 (6.73%)
Market Cap 1.20B
Revenue (ttm) 0.00
Net Income (ttm) -122.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 326,770
Avg Vol 974,398
Day's Range N/A - N/A
Shares Out 57.60M
Stochastic %K 45%
Beta -1.88
Analysts Strong Sell
Price Target $76.00

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in pre...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 1978
Address:
601 Gateway Boulevard, Suite 900, South San Francisco, United States
BiotechInvestor94
BiotechInvestor94 Sep. 15 at 6:00 PM
$MTSR $VKTX $GPCR I'm honestly bullish for all 3. They all have pros and cons but each has selling factors. Metsera has combinability, low API, dosing. Structure has low COGS (small molecule) with the ability to have better results at the highest dose of Aleniglipron compared to orforglipron (IF tolerability is okay with their slower titration schedule for 2B). Viking between the 3 as it stands, has the most clinically advanced pipeline (Phase 3 study well underway), and best efficacy and tolerability (despite the short attack on discontinuation which is more about trial design). Viking in comparison to Metsera is more affordable market cap wise although I like Metsera better long term. In my opinion devaluation was due to Obesity "bubble pop" by Novo flops which encouraged shorts and sell off pressure. The TAM for these drugs are too high though, eventually the new bull run will happen. I anticipate a biotech bull run from Obesity and from breakthroughs in AI drugs from some TechBios.
0 · Reply
BiotechInvestor94
BiotechInvestor94 Sep. 15 at 5:58 AM
$GPCR Wellington owns a lot of shares and its less competition in the oral space than the crowded injectables. I like Metsera alot but TAM and market penetration matter for return on investment. Overall I think Metsera the better long term differentiated play but structure could give better returns quicker. Structure valued 3 times as less too, so more affordable for BP partnership and/or buyout although they are prioritizing a partnership strategy per CEO comments this year.
0 · Reply
highnihilism
highnihilism Sep. 10 at 11:34 AM
$GPCR Nothing material. Claims it’s funded through 2027 while inching a Phase 2b obesity study toward Q4 2025 data. Biotech’s favorite pastime: burn cash, promise results. #ETSY Etsy’s platform engagement & merchant growth are reinforcing the $72 level. Consumer-spending resilience (whimsigoth, fetish fashion, handmade crafts, domestic charm). #SG Sweetgreen’s luxury athleisure lifestyle setting: bright & clean interior, crisp greens, bright wooden textures (post-class vibe) is reinforcing the $18 level. Where energized femininity resonates. #XHB Homebuilder demand trends & housing supply dynamics are reinforcing the $120 level. Fed rate-cut speculation & “golden cross” approaching. #BTC Bitcoin’s on-chain metrics & institutional flows are propping up the $112,000 level. Fed rate-cut speculation & “liquidity expansion.”
0 · Reply
BiotechInvestor94
BiotechInvestor94 Sep. 8 at 6:45 PM
$GPCR starting to like this opportunity given how much praise Lily has for Orfo. The trial for 2b has a very favorable titration schedule and will use the better formulation capsule. Also have the higher doses to increase odds of best in class efficacy as long as safety profile holds up.
0 · Reply
Quantumup
Quantumup Sep. 8 at 11:32 AM
Cantor Fitzgerald reiterated $GPCR Overweight-$65 and said, $GPCR has a big catalyst by year-end 2025 - P2B obesity readouts (ACCESS-1 and ACCESS-2 trials) for oral GLP-1 aleniglipron. $LLY $VKTX $NVO $TERN Cantor Fitzgerald added, $GPCR valuation at $1.3B market cap (EV of~$500M) remains very attractive into this catalyst. Recent orfor obesity data has created a better set-up for $GPCR with risk/reward meaningfully skewed to the upside as the bar for aleniglipron is no longer high. 2026 will have several readouts that can really differentiate $GPCR's pipeline - oral amylin, longer duration readout for higher doses of aleniglipron.
1 · Reply
fullmetalll
fullmetalll Sep. 5 at 8:59 PM
$GPCR PT Long €60
0 · Reply
Molllz_smartmoney
Molllz_smartmoney Sep. 5 at 7:02 PM
$GPCR Trade Idea 💡 Entry: 21.50 🟢 Profit Target 1: 23.47 🎯 Profit Target 2: 24.85 🚀 Profit Target 3: 26.98 🏆 Stop Loss: 18.32 🔴
0 · Reply
Meltingflame
Meltingflame Sep. 5 at 5:06 PM
$GPCR I hope news drops next week. Moonshot ✨
1 · Reply
outlawinvestor1
outlawinvestor1 Sep. 5 at 4:35 PM
$GPCR great discussion at cantor conference. really gave me more confidence in my position. i think there may be a possibility that their upcoming results disappoint investors; however, i would see it as a buying opportunity if that is the case. their lead and pipeline are strong and will definitely attract a partner, at their current levels. https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=33092681&checkCompany=1&checkEmail=1&checkName=1
0 · Reply
Theflash88
Theflash88 Sep. 4 at 8:07 PM
$GPCR Doing better lately.. I expect something to happen soon.
0 · Reply
Latest News on GPCR
Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 10, 2025, 1:54 PM EDT - 5 days ago

Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 6, 2025, 4:01 PM EDT - 5 weeks ago

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jun 23, 2025, 6:10 PM EDT - 3 months ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN LLY NVO PFE REGN VKTX XBI

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Jun 20, 2025, 7:30 PM EDT - 3 months ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

Apr 14, 2025, 10:49 AM EDT - 5 months ago

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

VKTX

Biotech stocks have been hit hard. Why they're a great value now.

Mar 27, 2025, 7:40 AM EDT - 6 months ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN DNLI INSM MRK SWTX

Structure Therapeutics CEO on latest GLP-1 developments

Mar 24, 2025, 6:26 PM EDT - 6 months ago

Structure Therapeutics CEO on latest GLP-1 developments

Final Trade: PYPL, UBER, NKE, GPCR

Mar 24, 2025, 6:23 PM EDT - 6 months ago

Final Trade: PYPL, UBER, NKE, GPCR

NKE PYPL UBER

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Mar 20, 2025, 9:28 AM EDT - 6 months ago

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Jan 30, 2025, 8:30 AM EST - 8 months ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

Jan 6, 2025, 2:53 PM EST - 9 months ago

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

VKTX

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Dec 17, 2024, 4:01 PM EST - 9 months ago

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Structure CEO on the competitive landscape for oral GLP-1 drugs

Dec 5, 2024, 6:17 PM EST - 10 months ago

Structure CEO on the competitive landscape for oral GLP-1 drugs

NVO

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 15, 2024, 8:30 AM EST - 10 months ago

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Nov 13, 2024, 4:01 PM EST - 10 months ago

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Oct 22, 2024, 2:07 PM EDT - 11 months ago

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP SRRK VKTX

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Aug 23, 2024, 3:17 PM EDT - 1 year ago

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Structure Therapeutics CEO on GLP drugs

Jun 11, 2024, 6:37 PM EDT - 1 year ago

Structure Therapeutics CEO on GLP drugs

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Jun 7, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Jun 5, 2024, 7:53 PM EDT - 1 year ago

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Jun 3, 2024, 6:27 PM EDT - 1 year ago

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Jun 3, 2024, 4:09 PM EDT - 1 year ago

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Structure Therapeutics reports promising weight-loss drug data

Jun 3, 2024, 2:38 PM EDT - 1 year ago

Structure Therapeutics reports promising weight-loss drug data

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Jun 3, 2024, 8:42 AM EDT - 1 year ago

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Jun 3, 2024, 7:30 AM EDT - 1 year ago

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

May 7, 2024, 11:33 AM EDT - 1 year ago

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

AMGN LLY NVO ALT AZN VKTX

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

Apr 16, 2024, 7:09 PM EDT - 1 year ago

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

AMGN AZN LLY NVO PFE SNY VKTX

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

Mar 9, 2024, 2:30 AM EST - 1 year ago

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

NVO PFE VKTX

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Mar 8, 2024, 4:05 PM EST - 1 year ago

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Mar 8, 2024, 8:30 AM EST - 1 year ago

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

Jan 17, 2024, 3:40 PM EST - 1 year ago

The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

VKTX TERN

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

Dec 20, 2023, 11:17 AM EST - 1 year ago

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

LLY NVO ALT AMGN VKTX

Structure Therapeutics reports promising results for weight-loss pill

Dec 18, 2023, 11:56 AM EST - 1 year ago

Structure Therapeutics reports promising results for weight-loss pill

New Shakeup Hits Obesity Pills. Structure Rolls Out Disappointing Data.

Dec 18, 2023, 11:29 AM EST - 1 year ago

New Shakeup Hits Obesity Pills. Structure Rolls Out Disappointing Data.

Structure's diabetes pill misses weight-loss expectations in mid-stage trial

Dec 18, 2023, 10:37 AM EST - 1 year ago

Structure's diabetes pill misses weight-loss expectations in mid-stage trial

Structure Therapeutics stock plunges on new GLP-1 drug data

Dec 18, 2023, 8:04 AM EST - 1 year ago

Structure Therapeutics stock plunges on new GLP-1 drug data

Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

Dec 18, 2023, 7:30 AM EST - 1 year ago

Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Nov 14, 2023, 4:10 PM EST - 1 year ago

Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Structure Therapeutics: Tipping The Scales In Obesity Management

Oct 3, 2023, 11:28 PM EDT - 2 years ago

Structure Therapeutics: Tipping The Scales In Obesity Management

Final Trades: Rivian, Pfizer, Treasury Bonds and more

Sep 29, 2023, 6:26 PM EDT - 2 years ago

Final Trades: Rivian, Pfizer, Treasury Bonds and more

PFE RIVN TLT

Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data

Sep 29, 2023, 12:02 PM EDT - 2 years ago

Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data

Structure Therapeutics surges on promising early stage obesity drug data

Sep 29, 2023, 10:15 AM EDT - 2 years ago

Structure Therapeutics surges on promising early stage obesity drug data

Structure Therapeutics shares surge after positive results in weight-loss trial, $300 million private placement

Sep 29, 2023, 8:02 AM EDT - 2 years ago

Structure Therapeutics shares surge after positive results in weight-loss trial, $300 million private placement

Structure Therapeutics Announces $300 Million Private Placement Equity Financing

Sep 29, 2023, 7:32 AM EDT - 2 years ago

Structure Therapeutics Announces $300 Million Private Placement Equity Financing

Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update

Sep 29, 2023, 7:30 AM EDT - 2 years ago

Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update

Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

BiotechInvestor94
BiotechInvestor94 Sep. 15 at 6:00 PM
$MTSR $VKTX $GPCR I'm honestly bullish for all 3. They all have pros and cons but each has selling factors. Metsera has combinability, low API, dosing. Structure has low COGS (small molecule) with the ability to have better results at the highest dose of Aleniglipron compared to orforglipron (IF tolerability is okay with their slower titration schedule for 2B). Viking between the 3 as it stands, has the most clinically advanced pipeline (Phase 3 study well underway), and best efficacy and tolerability (despite the short attack on discontinuation which is more about trial design). Viking in comparison to Metsera is more affordable market cap wise although I like Metsera better long term. In my opinion devaluation was due to Obesity "bubble pop" by Novo flops which encouraged shorts and sell off pressure. The TAM for these drugs are too high though, eventually the new bull run will happen. I anticipate a biotech bull run from Obesity and from breakthroughs in AI drugs from some TechBios.
0 · Reply
BiotechInvestor94
BiotechInvestor94 Sep. 15 at 5:58 AM
$GPCR Wellington owns a lot of shares and its less competition in the oral space than the crowded injectables. I like Metsera alot but TAM and market penetration matter for return on investment. Overall I think Metsera the better long term differentiated play but structure could give better returns quicker. Structure valued 3 times as less too, so more affordable for BP partnership and/or buyout although they are prioritizing a partnership strategy per CEO comments this year.
0 · Reply
highnihilism
highnihilism Sep. 10 at 11:34 AM
$GPCR Nothing material. Claims it’s funded through 2027 while inching a Phase 2b obesity study toward Q4 2025 data. Biotech’s favorite pastime: burn cash, promise results. #ETSY Etsy’s platform engagement & merchant growth are reinforcing the $72 level. Consumer-spending resilience (whimsigoth, fetish fashion, handmade crafts, domestic charm). #SG Sweetgreen’s luxury athleisure lifestyle setting: bright & clean interior, crisp greens, bright wooden textures (post-class vibe) is reinforcing the $18 level. Where energized femininity resonates. #XHB Homebuilder demand trends & housing supply dynamics are reinforcing the $120 level. Fed rate-cut speculation & “golden cross” approaching. #BTC Bitcoin’s on-chain metrics & institutional flows are propping up the $112,000 level. Fed rate-cut speculation & “liquidity expansion.”
0 · Reply
BiotechInvestor94
BiotechInvestor94 Sep. 8 at 6:45 PM
$GPCR starting to like this opportunity given how much praise Lily has for Orfo. The trial for 2b has a very favorable titration schedule and will use the better formulation capsule. Also have the higher doses to increase odds of best in class efficacy as long as safety profile holds up.
0 · Reply
Quantumup
Quantumup Sep. 8 at 11:32 AM
Cantor Fitzgerald reiterated $GPCR Overweight-$65 and said, $GPCR has a big catalyst by year-end 2025 - P2B obesity readouts (ACCESS-1 and ACCESS-2 trials) for oral GLP-1 aleniglipron. $LLY $VKTX $NVO $TERN Cantor Fitzgerald added, $GPCR valuation at $1.3B market cap (EV of~$500M) remains very attractive into this catalyst. Recent orfor obesity data has created a better set-up for $GPCR with risk/reward meaningfully skewed to the upside as the bar for aleniglipron is no longer high. 2026 will have several readouts that can really differentiate $GPCR's pipeline - oral amylin, longer duration readout for higher doses of aleniglipron.
1 · Reply
fullmetalll
fullmetalll Sep. 5 at 8:59 PM
$GPCR PT Long €60
0 · Reply
Molllz_smartmoney
Molllz_smartmoney Sep. 5 at 7:02 PM
$GPCR Trade Idea 💡 Entry: 21.50 🟢 Profit Target 1: 23.47 🎯 Profit Target 2: 24.85 🚀 Profit Target 3: 26.98 🏆 Stop Loss: 18.32 🔴
0 · Reply
Meltingflame
Meltingflame Sep. 5 at 5:06 PM
$GPCR I hope news drops next week. Moonshot ✨
1 · Reply
outlawinvestor1
outlawinvestor1 Sep. 5 at 4:35 PM
$GPCR great discussion at cantor conference. really gave me more confidence in my position. i think there may be a possibility that their upcoming results disappoint investors; however, i would see it as a buying opportunity if that is the case. their lead and pipeline are strong and will definitely attract a partner, at their current levels. https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=33092681&checkCompany=1&checkEmail=1&checkName=1
0 · Reply
Theflash88
Theflash88 Sep. 4 at 8:07 PM
$GPCR Doing better lately.. I expect something to happen soon.
0 · Reply
morelong_lessshort
morelong_lessshort Aug. 31 at 6:45 PM
$GPCR $VKTX Your evaluation of the market, Viking and Viking competition completely changed from previous comments made about 10 days ago. I thought it was a spam account, but no.
0 · Reply
Theflash88
Theflash88 Aug. 28 at 7:55 PM
$GPCR Imo they’re not “astute at anything!” Look at the stock chart..
0 · Reply
ContrarianChamp
ContrarianChamp Aug. 27 at 6:47 AM
$GPCR sitting near support, reaction here will be critical.
0 · Reply
Quantumup
Quantumup Aug. 26 at 4:49 PM
$LLY $NVO $VKTX $GPCR $TERN ZLDPY AMGN RHHBY PFE AZN MRK William Blair: In what we view as yet another surprising development, orforglipron outperformed investor expectations in patients living with both overweight/obesity and type 2 diabetes, which we view as the higher-risk and more difficult-to-treat population. Based on contemporary epidemiology, roughly a quarter of overweight/obese individuals also have type 2 diabetes. Accounting for the three Phase III studies of orforglipron, we believe the franchise exhibited the highest competitive advantage in diabetes (roughly 15% of the U.S. adult population). Furthermore, patients living with type 2 diabetes often have comorbid conditions (such as hypertension or dyslipidemia), which are most commonly managed with oral medications. It is therefore our opinion that orforglipron could be seamlessly incorporated into patients' daily routines, thereby encouraging uptake.
0 · Reply
biolover
biolover Aug. 26 at 1:52 PM
$VKTX volume 1.5 m in 15 mints vs 15 k in $GPCR that should react more to $LLY news ? Something mysterious.
0 · Reply
biolover
biolover Aug. 22 at 10:47 PM
$VKTX Reminder $GPCR oral GLP1 agonist ( replica of $LLY orfoglipron) got 6-7% wt loss at 12 wks in phase 2a despite rapid escalation and with 60% Vomiting and with no placebo effect .. $PFE Danu with rapid escalation resulted in 3.7% wt loss at 12 wks with 45% vomiting Just to place them all in comparison to $VKTX oral VK2735 …
0 · Reply
DAR2487
DAR2487 Aug. 21 at 10:41 PM
$GPCR sure seems like alot of buyers have been getting in. This will likely grind up to mid 20s before news sends this back to 50+
0 · Reply
PrnceMichael
PrnceMichael Aug. 21 at 4:15 PM
$PFSA Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform $GPCR $PFSA $VKTX https://www.benzinga.com/pressreleases/25/08/ab47180683/profusa-inc-nasdaq-pfsa-establishes-a-distributor-partner-in-spain-for-lumee-oxygen-platform?utm_source=articleShare via @Benzinga @MrSamuelPowers @ProfusaInc @Nasdaq
0 · Reply
biolover
biolover Aug. 21 at 12:53 PM
$GPCR $RYTM $SLNO $VKTX RYTM drug total rip off $ 400,000-500000 per year for wt loss in syndrome obesity. This is how the health care operates. Obviously supported by many bio hedge funds hoping for BO. I don’t believe this malfunctioning price disparity will last.
1 · Reply
Quantumup
Quantumup Aug. 21 at 12:38 PM
Citizens reiterated $RYTM Market Outperform-$135 and said: We are pleased that the FDA accepted the sNDA and the Priority Review speaks to the unmet need and strength of the setmelanotide submission. LLY $VKTX NVO $GPCR TERN $AARD $SLNO Citizens added:
0 · Reply